Golan et al. reviewed clinical outcomes in a series of 71 PC patients harboring BRCA1/BRCA2 mutation, and reported that stage 3/4 patients receiving a platinum regimen had significantly longer OS than those receiving a non-platinum regimen (median OS: 22 months vs. 9 months) [79]. Here, BRCA2 is linked to pachyonychia congenita.